MRA Advisory Group Sells 947 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

MRA Advisory Group trimmed its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 56.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 745 shares of the medical equipment provider’s stock after selling 947 shares during the quarter. MRA Advisory Group’s holdings in Intuitive Surgical were worth $331,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Advisors Asset Management Inc. boosted its holdings in Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock valued at $2,945,000 after acquiring an additional 1,129 shares during the period. Public Employees Retirement System of Ohio grew its holdings in Intuitive Surgical by 5.4% in the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock valued at $64,531,000 after buying an additional 9,869 shares during the last quarter. HCR Wealth Advisors boosted its position in shares of Intuitive Surgical by 26.3% in the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock valued at $352,000 after acquiring an additional 217 shares during the period. Checchi Capital Advisers LLC grew its stake in shares of Intuitive Surgical by 2.5% in the fourth quarter. Checchi Capital Advisers LLC now owns 2,875 shares of the medical equipment provider’s stock worth $970,000 after acquiring an additional 70 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Intuitive Surgical by 0.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 519,807 shares of the medical equipment provider’s stock worth $175,364,000 after acquiring an additional 4,335 shares during the period. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Price Performance

Shares of ISRG opened at $471.82 on Friday. The company has a market capitalization of $167.35 billion, a P/E ratio of 85.17, a PEG ratio of 5.43 and a beta of 1.39. The business’s 50 day simple moving average is $458.74 and its 200-day simple moving average is $418.27. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $493.97.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s quarterly revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.18 earnings per share. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total transaction of $90,655.48. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,655,048.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $482.21, for a total transaction of $90,655.48. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,655,048.26. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. In the last three months, insiders sold 51,656 shares of company stock valued at $24,700,644. 0.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of research reports. Evercore ISI reduced their price target on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a report on Friday, July 19th. JPMorgan Chase & Co. lifted their target price on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Morgan Stanley upped their price target on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Barclays lifted their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Finally, The Goldman Sachs Group assumed coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.